HRSA responds to AHA outreach regarding Johnson & Johnson’s unilateral imposition of 340B rebate model 

Aug 23, 2024 - 02:34 PM
340B pic

Johnson & Johnson announced Aug. 23 that it would be fundamentally changing the way it makes 340B pricing available for two of its most popular products, Stelara and Xarelto. Starting Oct. 15, J&J will require all disproportionate share hospitals participating in the 340B Drug Pricing Program to purchase these drugs at full price and submit data to J&J. Upon verification of the drug’s 340B status, DSHs would receive a rebate for the discounted 340B price.

Last week, the AHA contacted the Health Resources and Services Administration for more information as soon as it was made aware that J&J was considering these actions. HRSA notified the AHA today that it has informed J&J that its rebate model is inconsistent with the 340B statute and that this model has not been approved by the Secretary of the Department of Health and Human Services. HRSA further informed the AHA that it will take appropriate action as warranted.
 

Related News Articles

Headline
Washington Post publishes AHA letter in response to anti-340B editorial
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
AHA urges HRSA to abandon 340B rebate model that will cost billions and jeopardize access to care for millions
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
AHA urges en banc review of 4th Circuit’s West Virginia 340B contract pharmacy law decision
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…
Headline
Mississippi 340B law upheld by appeals court in two cases
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
Court strikes HRSA 340B policy restricting initial hospital drug purchases through GPOs
The U.S. District Court for the District of Columbia March 31 vacated a Health Resources and Services Administration policy instituted in 2013 that restricted…
Headline
4th Circuit upholds block on West Virginia’s 340B law
The U.S. Court of Appeals for the 4th Circuit March 31 upheld a preliminary injunction issued by the U.S. District Court for the District of West Virginia…